Roche Holding AG (VIE:ROGP)
Austria · Delayed Price · Currency is EUR | Market Cap | 347.59B +50.2% |
| Revenue (ttm) | 68.20B -0.8% |
| Net Income | 13.37B +30.9% |
| EPS | 16.61 +30.6% |
| Shares Out | n/a |
| PE Ratio | 26.24 |
| Forward PE | 18.67 |
| Dividend | 10.85 (2.49%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | n/a |
| Open | 434.00 |
| Previous Close | 432.00 |
| Day's Range | 434.00 - 436.00 |
| 52-Week Range | 279.10 - 436.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Jan 29, 2027 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma
Basel, 28 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the global launch of the VENTANA BAP1 (SP527)* test. This automated, ready-to-use immunohistochemistry (IHC) assay provides ...
Roche receives CE Mark for cobas smart e immunoanalyser
Roche (RHHBY) announced that it has received the CE Mark for its cobas smart e immunoanalyser, a compact, standalone platform engineered to deliver reliable testing with a planned menu of…
Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories
Basel, 27 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has received the CE Mark for its cobas smart e immunoanalyser, a compact, standalone platform engineered to deliver ...
Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
The Swiss drugmaker expects a pill it is developing to become the new standard treatment for an advanced form of lung cancer, and the company's first shot at an emerging field within the oncology mark...
Genentech says Phase III Krascendo 1 study met primary, secondary endpoints
Genentech, a member of the Roche (RHHBY) Group, announced results from the Phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational divarasib, a next-generation KRAS G1...
Roche says divarasib cut risk of death 44% in lung cancer trial
Swiss drugmaker Roche said on Sunday its experimental lung cancer drug divarasib reduced the risk of death by 44% compared with existing treatments in a phase III study.
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Divarasib demonstrated best-in-class efficacy in Phase III trial, advancing the standard of care in previously treated KRAS G12C-mutated lung c...
Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
Basel, 25 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today pivotal results from the phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational divarasib,...
Zymeworks price target raised to $52 from $50 at Jefferies
Jefferies raised the firm’s price target on Zymeworks (ZYME) to $52 from $50 and keeps a Buy rating on the shares. The company and Roche (RHHBY) entered into an exclusive…
Roche says Sefaxersen trial shows meaningful reduction in proteinuria
Ionis Pharmaceuticals (IONS) partner Roche (RHHBY) announced late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults with primary IgA nephropathy receiving optimized ...
Roche reports Sefaxersen achieved 43.1% reduction in proteinuria in trial
Roche (RHHBY) announced late-breaking oral presentation data from the ongoing phase III IMAgINATION study in adults with primary IgA nephropathy receiving optimized standard of care, demonstrating tha...
Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today late-breaking oral presentation data from the ongoing Phase III IMAgI...
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Basel, 23 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today late-breaking oral presentation data from the ongoing phase III IMAgINATION study in adults with primary IgA nephropathy (Ig...
Zymeworks signs collaboration and license agreement with Roche for ZW209
Zymeworks (ZYME) announced that it has entered into a global license and collaboration agreement with Roche (RHHBY) for the research, development and commercialization of ZW209, a T cell engager targe...
Roche upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Roche (RHHBY) to Buy from Hold with a price target of CHF 500, up from CHF 340, post the Q3 report. The firm says physician feedback on…
Roche Holding AG Earnings Call Transcript: Q3 2026
YTD sales rose 6% at CER, with Pharma growth offsetting Diagnostics pricing pressure in China; Q3 included a temporary Japan shipment-timing benefit. Guidance was reaffirmed, with margins expected to expand next year and pipeline progress supporting growth into 2030.
Roche Holding AG Earnings release: Q3 2026
Roche Holding AG released its Q3 2026 earnings on October 22, 2026, summarizing the period's financial results.
Roche Holding AG Slides: Q3 2026
Roche Holding AG has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 22, 2026.
Roche reports 9M group sales CHF 46.5B vs. CHF 45.9B last year
In the first nine months of 2026, Roche (RHHBY) sales were +6% at CER, +1% when reported in CHF, to CHF 46.5B due to strong demand for pharmaceutical products and…
Roche confirms FY26 outlook
Roche (RHHBY) expects an increase in Group sales in the mid single digit range for 2026. Core earnings per share are targeted to develop in the high single digit range.
Roche Posts Higher Sales on Growth Across Pharma, Diagnostics Units
Roche reiterated its full-year guidance and said it is prepared to launch its giredestrant breast-cancer pill later this year.
Roche third quarter sales slightly beat expectations with growth across divisions
Swiss drugmaker Roche beat third-quarter sales expectations on Thursday, supported by steady demand for key medicines such as Ocrevus to buy time as it looks abroad to restock a pipeline facing loom...
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]
Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine months of 2...
Genentech announces new Phase III data for fenebrutinib
Genentech, a member of the Roche (RHHBY) Group, announced new Phase III data for investigational fenebrutinib in multiple sclerosis, demonstrating reduced markers of chronic brain inflammation as well...
Roche says experimental MS pill cuts relapses by 55% in late-stage trials
Roche said on Wednesday late-stage trial data showed its experimental drug fenebrutinib reduced markers of chronic brain inflammation and delivered broader disease control than comparator treatments...